KaydedilenlerDerginizi ekleyin

Dergiler / Erciyes Medical Journal / 2021 / Cilt: 43 - Sayı: 2

Epidermal Growth Factor-Like Repeats andDiscoidin I-Like Domains 3 is a Novel Regulator of Epithelial-Mesenchymal Transition in Clear Cell Renal Cell Carcinoma: In Silico Analysis

Dilara Fatma Akın BALI
Rahşan Ilıkçı SAĞKAN
Sayfa
122–129
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

EDIL3 can be used as a diagnostic or prognosticindicator of cancer development to help cure renal clear cell cancer.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Epithelial-mesenchymal transition (EMT) contributes to cancer metastasis and recurrence, which are major obsta cles in changing the course of cancer.
📊
Temel Bulgular & Veri:However, studies on the mutational and gene expression profiles of epidermal growthfactor-like repeats and discoidin I-like domains 3 (EDIL3) that reveal the relationship between clear cell renal cell carcinoma(ccRCC) and EMT markers are limited.
💡
Sonuç & Katkı:EDIL3 can be used as a diagnostic or prognosticindicator of cancer development to help cure renal clear cell cancer.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Epithelial-mesenchymal transition (EMT) contributes to cancer metastasis and recurrence, which are major obsta cles in changing the course of cancer. However, studies on the mutational and gene expression profiles of epidermal growthfactor-like repeats and discoidin I-like domains 3 (EDIL3) that reveal the relationship between clear cell renal cell carcinoma(ccRCC) and EMT markers are limited. The aim of our study was to reveal the correlation between tumor and EMT markers(E-cadherin and vimentin) and EDIL3 expression. Additionally, we evaluated target gene expression levels and mutationalprofiles in kidney cancer tissue and normal tissue. Materials and Methods: We investigated the mutational profile and mRNA expression of EDIL3 and compared them withthat of VIM and CDH1 in 523 patients with ccRCC using validated bioinformatics analysis. Additionally, PolymorphismPhenotyping v2 (PolyPhen-2), Screening for NonAcceptable Polymorphisms (SNAP) were used to predict and confirm thepathogenicity of the mutations detected. Studies were performed in silico using bioinformatics tools. Results: EDIL3 and VIM expression was statistically significantly higher in the healthy group and exhibited a positive cor relation in patients with ccRCC. Patients with elevated VIM and CDH1 expression and low EDIL3 expression had prolongedsurvival time. In addition, 7 mutations were detected in the evaluated genes, 6 of which had potential pathogenic features. Conclusion: Our study provides insights for further experimental studies. EDIL3 can be used as a diagnostic or prognosticindicator of cancer development to help cure renal clear cell cancer.

🔖

Bu Makaleye Atıf Yap

BALI, D. F. A., SAĞKAN, R. I. (2022). Epidermal Growth Factor-Like Repeats andDiscoidin I-Like Domains 3 is a Novel Regulator of Epithelial-Mesenchymal Transition in Clear Cell Renal Cell Carcinoma: In Silico Analysis. Erciyes Medical Journal, Cilt: 43 - Sayı: 2, 122–129. https://ajindex.com/articles/502291

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Spadaccino F, Netti GS, Rocchetti MT, Castellano G, Stallone G, Ranieri E. [Article in Italian]. G Ital Nefrol 2020; 37(2): 2020–vol2
  2. Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of Renal Cell Carcinoma. Eur Urol 2019; 75(1): 74–84
  3. Piva F, Giulietti M, Santoni M, Occhipinti G, Scarpelli M, Lopez-Beltran A, et al. Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy. Mol Diagn Ther 2016; 20(2): 111–7
  4. He H, Magi-Galluzzi C. Epithelial-to-mesenchymal transition in renal neoplasms. Adv Anat Pathol 2014; 21(3): 174–80
  5. Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, et al. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. Cells 2019; 8(10): 1118
  6. Feng YL, Chen DQ, Vaziri ND, Guo Y, Zhao YY. Small molecule inhibitors of epithelial-mesenchymal transition for the treatment of cancer and fibrosis. Med Res Rev 2020; 40(1): 54–78
  7. Parsana P, Amend SR, Hernandez J, Pienta KJ, Battle A. Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration. BMC Cancer 2017; 17(1): 447
  8. Jiang SH, Wang Y, Yang JY, Li J, Feng MX, Wang YH, et al. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Oncotarget 2016; 7(4): 4226–40
  9. Zhang R, Wei YH, Zhao CY, Song HY, Shen N, Cui X, et al. EDIL3 depletion suppress epithelial-mesenchymal transition of lens epithelial cells via transforming growth factor β pathway. Int J Ophthalmol 2018; 11(1): 18–24
  10. Sun JC, Liang XT, Pan K, Wang H, Zhao JJ, Li JJ, et al. High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients. World J Gastroenterol 2010; 16(36): 4611–5
  11. Lee SH, Kim DY, Jing F, Kim H, Yun CO, Han DJ, Choi EY. Del-1 overexpression potentiates lung cancer cell proliferation and invasion. Biochem Biophys Res Commun 2015; 468(1-2): 92–8
  12. Lee SJ, Lee J, Kim WW, Jung JH, Park HY, Park JY, et al. Del-1 Expression as a Potential Biomarker in Triple-Negative Early Breast Cancer. Oncology 2018; 94(4): 243–56
  13. Zou X, Qiao H, Jiang X, Dong X, Jiang H, Sun X. Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer. J Biomed Sci 2009; 16(1): 33
  14. Oplawski M, Dziobek K, Zmarzły N, Grabarek B, Tomala B, Leśniak E, et al. Eva